BEGIN:VCALENDAR
VERSION:2.0
METHOD:PUBLISH
PRODID:-//Telerik Inc.//Sitefinity CMS 14.4//EN
BEGIN:VTIMEZONE
TZID:Mountain Standard Time
BEGIN:STANDARD
DTSTART:20251102T020000
RRULE:FREQ=YEARLY;BYDAY=1SU;BYHOUR=2;BYMINUTE=0;BYMONTH=11
TZNAME:Mountain Standard Time
TZOFFSETFROM:-0600
TZOFFSETTO:-0700
END:STANDARD
BEGIN:DAYLIGHT
DTSTART:20250301T020000
RRULE:FREQ=YEARLY;BYDAY=2SU;BYHOUR=2;BYMINUTE=0;BYMONTH=3
TZNAME:Mountain Daylight Time
TZOFFSETFROM:-0700
TZOFFSETTO:-0600
END:DAYLIGHT
END:VTIMEZONE
BEGIN:VEVENT
DESCRIPTION:Experts in lymphomas\, plasma cell disorders\, myeloproliferati
 ve neoplasms\, acute myeloid leukemia\, myelodysplastic syndrome\, and coa
 gulation disorders will provide exciting updates from ASH 2019 with a focu
 s on the latest treatment advances relevant to your clinical practice. The
  day will include presentations\, case reviews\, and interactive question 
 and answer sessions. ____________________ By the end of the review\, atten
 dees will be better equipped to: Identify which patients with hematologic 
 malignancy may benefit from specific targeted therapies. Recognize myriad 
 of presentations of patients with hematologic malignancy. Identify higher 
 risk patients with hematologic malignancy and know best available therapie
 s for these patients. Recognize best current approach to patients requirin
 g more aggressive treatments. Prescribe individualized plans for patients 
 with hematologic malignancies based on specific disease characteristics (g
 enetics\, molecular markers). Manage complications of hematologic malignan
 cies in an outpatient setting.
DTEND:20200201T213000Z
DTSTAMP:20260316T140219Z
DTSTART:20200201T143000Z
LOCATION:
SEQUENCE:0
SUMMARY:Review of 2019 American Society of Hematology Annual Meeting
UID:RFCALITEM639092665395267568
X-ALT-DESC;FMTTYPE=text/html:Experts in lymphomas\, plasma cell disorders\,
  myeloproliferative neoplasms\, acute myeloid leukemia\, myelodysplastic s
 yndrome\, and coagulation disorders will provide exciting updates from ASH
  2019 with a focus on the latest treatment advances relevant to your clini
 cal practice. The day will include presentations\, case reviews\, and inte
 ractive question and answer sessions. ____________________ By the end of t
 he review\, attendees will be better equipped to: Identify which patients 
 with hematologic malignancy may benefit from specific targeted therapies. 
 Recognize myriad of presentations of patients with hematologic malignancy.
  Identify higher risk patients with hematologic malignancy and know best a
 vailable therapies for these patients. Recognize best current approach to 
 patients requiring more aggressive treatments. Prescribe individualized pl
 ans for patients with hematologic malignancies based on specific disease c
 haracteristics (genetics\, molecular markers). Manage complications of hem
 atologic malignancies in an outpatient setting.
END:VEVENT
END:VCALENDAR